C. Eng, D. Clayton, I. Schuffenecker, et al., “The Relationship between Specific Ret Proto-Oncogene Mutations and Disease Phenotype in Multiple Endocrine Neoplasia Type 2. International Ret Mutation Consortium Analysis,” Journal of the American Medical Association, Vol. 276, No. 19, 1996, pp. 1575-1579. doi:10.1001/jama.276.19.1575

has been cited by the following article:

• TITLE: Novel p.C620L RET Mutation Detected in a Patient with Medullary Thyroid Carcinoma

  AUTHORS: Rebecca L. Margraf, Patti M. F. Krautscheid, David C. Pattison, Karl V. Voelkerding, Rong Mao

  KEYWORDS: RET; MEN2; MTC; Medullary Thyroid Carcinoma; High Resolution Melting Analysis; Inherited Thyroid Cancer

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.3 No.6, November 21, 2012

  ABSTRACT: A patient with an apparent sporadic medullary thyroid carcinoma was tested for RET germline mutations by Sanger sequencing of RET exons 10, 11, and 13-16. The patient was heterozygous for two known mutations causative of Multiple Endocrine Neoplasia type 2 disorder, and both mutations were within codon 620 of RET exon 10, c.1859G > T (p.C620F) and c.1860C > G (p.C620W). In order to determine if these adjacent mutations were in cis or in trans, an unlabeled probe method and high-resolution melting analysis were utilized. The mutations were confirmed to occur in cis, representing a novel mutation, c.1859_1860delinsTG (p.C620L). Sanger sequencing of parental samples did not identify any changes at codon 620, so the p.C620L mutation is also de novo. The early age of onset for medullary thyroid carcinoma and the presence of lymph node metastasis in this patient suggests individuals with the p.C620L mutation should be treated and screened (for pheochromocytomas and parathyroid hyperplasia) as Multiple Endocrine Neoplasia type 2 patients with other RET codon 620 mutations (American Thyroid Association risk level B).